Dana-Farber registers Phase 2 zanzalintinib trial for rare adrenal tumors, Exelixis collaborating

This week's only registry update concerns a newly posted trial of Exelixis's zanzalintinib in a rare tumor type, sponsored by an academic center with Exelixis as collaborator.

• A Phase 2 trial titled "A Phase 2 Clinical Trial of Zanzalintinib in Patients With Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma (MPPGs)" (NCT07714551) was first posted on 2026-07-20 and is sponsored by Dana-Farber Cancer Institute with Exelixis as collaborator. The study's overall status is not yet recruiting, with an estimated start date of 2027-01-09 and estimated primary completion date of 2031-01-01.¹ The trial is a single-arm study evaluating zanzalintinib, given orally at 60 mg once daily, in patients with unresectable and progressive metastatic pheochromocytoma or paraganglioma.¹ The study expects to enroll about 14 people.¹ The primary outcome is objective response rate, defined as the percentage of participants achieving complete or partial response based on RECIST 1.1 criteria.¹